Shahram Katousian

Shahram Katousian has over 20 years of experience in the biotechnology and pharmaceutical industry. Shahram is currently the Vice President and Head of CMC at enGene, where they oversee the Drug Product portfolio and provides strategic leadership for CMC activities. Previously, Shahram held senior positions at Halozyme Therapeutics, Inc., Abzena, Nektar Therapeutics, Medivation, Baxalta, Astellas Pharma US, Amgen, and Genentech. Throughout their career, they have demonstrated expertise in areas such as manufacturing strategy, process optimization, technology transfer, and business liaison. Shahram's accomplishments include cost savings of over $15M, successful management of commercial supply activities, and the development of new technologies and strategies to enhance productivity and quality.

Shahram Katousian pursued their education in Molecular Biology at the University of British Columbia from 1992 to 1998.